Live
Endpoints NewsKailera plans IPO for Phase 3 obesity drug from HengruiEndpoints News#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failureThermo FisherWedge Capital Management L L P NC Sells 6,634 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeatWatersWaters Corporation Q2 2013 Financial Results Webcast Invitation - AOL.comWatersSG Americas Securities LLC Acquires 31,459 Shares of Waters Corporation $WAT - MarketBeat10x Genomics BlogIs Ark Invest’s Steady Buying Reframing the Long-Term Product Expansion Story At 10x Genomics (TXG)? - simplywall.stEndpoints News#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodyFierceBiotechTakeda clears path to FDA with phase 3 data on $4B psoriasis betCellAdvancing precision health discovery in a genetically diverse health systemCellWhole-body molecular and cellular mapping of the laboratory mouseEndpoints News#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposureThermo FisherGenerate Investment Management Ltd Has $20.66 Million Stake in Thermo Fisher Scientific Inc. $TMO - MarketBeat
Endpoints News Mar 29, 2026

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Original
Body unavailable. Use the original source.

Directory

59 All